Matches in Nanopublications for { ?s ?p "DDI between Digoxin and Tolvaptan - Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. [drugbank_resource:DB00390_DB06212]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00390_DB06212 label "DDI between Digoxin and Tolvaptan - Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. [drugbank_resource:DB00390_DB06212]" assertion.